150 results on '"Follador, Alessandro"'
Search Results
2. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
3. The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice
4. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
5. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
6. Emerging therapies in malignant pleural mesothelioma
7. Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World
8. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study
9. Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study: Complementary and alternative medicine in oncology
10. Radiation Recall Pneumonitis Anticipates Bilateral Immune-Induced Pneumonitis in Non-Small Cell Lung Cancer
11. EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience
12. Immunotherapy in NSCLC Patients with Brain Metastases
13. Brain metastases from gastrointestinal tumours: Tailoring the approach to maximize the outcome
14. Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data: An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014)
15. First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study
16. Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy
17. Real-World Data on Treatment Outcomes in EGFR -Mutant Non-Small-Cell Lung Cancer Patients Receiving Osimertinib in Second or Further Lines
18. Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study
19. A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
20. A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients
21. Effects of the growing prevalence in oncology: A real-world study on the estimated workload.
22. PROTEOMIC ANALYSIS OF LARGE CORE BREAST BIOPSY SAMPLES: A FEASIBLE APPROACH WITH SEVERAL POTENTIAL APPLICATIONS
23. SCREENING FOR LUNG CANCER AND MESOTHELIOMA WITH LOW-DOSE SPIRAL COMPUTED TOMOGRAPHY (LDCT) IN 1000 ASBESTOS-EXPOSED WORKERS: AN ALPE-ADRIA THORACIC ONCOLOGY MULTIDISCIPLINARY GROUP STUDY (ATOM 002)
24. Real-world data on treatment outcomes in -mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.
25. Supplemental_Information – Supplemental material for Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program
26. Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial
27. Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach
28. Drug waste minimisation and cost-containment in Medical Oncology: Two-year results of a feasibility study
29. Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report
30. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program
31. Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers
32. Perception and opinions of health professionals of an Italian academic hospital about complementary and alternative medicine in oncology.
33. MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme
34. INTEGRATED CARE PATHWAYS IN LUNG CANCER: A QUALITY IMPROVEMENT PROJECT
35. Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example
36. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients. Results from a multicenter Italian observational study
37. A novel MGMT methylation-based prognostic score in patients with glioblastoma.
38. P1.03-035 Does Screening with Low-Dose Computed Tomography (LDCT) of Asbestos Exposed Subjects Reduce Mortality for Lung Cancer (LC)?
39. Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example
40. O33-1 Screening with low-dose computed tomography (ldct) of asbestos exposed subjects is associated with reduced lung cancer mortality
41. Risk of unplanned presentations and hospital admission in lung cancer patients: Insights from the experience of a single institution.
42. Screening with low-dose computed tomography (LDCT) of asbestos-exposed subjects and lung cancer (LC) mortality.
43. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients
44. Screening for lung cancer and pleural mesothelioma with low-dose spiral computer tomography (LDCT) in 1000 asbestos-exposed workers: An alpe-adria thoracic oncology multidisciplinary group study (ATOM002)
45. Drug waste minimization as an effective strategy of cost-containment in Oncology
46. A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe–Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019)
47. Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)
48. Fulminating Septic Shock from Clostridium Perfringens in an Early Breast Cancer Patient with Severe Myalgia after Docetaxel Treatment
49. Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer
50. Drug waste minimisation and cost-containment in Medical Oncology: Two-year results of a feasibility study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.